Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL FranchiseGlobeNewsWire • Thursday
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 10/30/26
Vor Bio says its experimental drug slowed loss of kidney function in late-stage studyReuters • 10/22/26
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA NephropathyGlobeNewsWire • 10/22/26
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia GravisGlobeNewsWire • 09/29/26
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia GravisGlobeNewsWire • 09/08/26
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/26
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market RealizesSeeking Alpha • 07/07/26
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in ChinaGlobeNewsWire • 06/08/26
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaGlobeNewsWire • 06/08/26
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineGlobeNewsWire • 05/14/26
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/26
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeZacks Investment Research • 05/07/26
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?Zacks Investment Research • 04/20/26
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should KnowZacks Investment Research • 04/02/26
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/30/26